Thus, for the breast cancer patients with low expression of IGFBP6 and ELOVL5 genes in cancer tissue the addition of PUFAs to the chemotherapy regimen can be potentially beneficial and should be tested in more clinically relevant settings. This evidence concerns the gene IGFBP6 and cancer.